


Next-generation gene sequencing

A provider of laboratory services worldwide, Source BioScience recently announced that it has acquired the next-generation sequencing services business from Oxford Gene Technology (OGT) in a move to expand its products and services portfolio. The transfer of business from OGT to Source BioScience should contribute to the continued success and organic growth of the company says Russell Wheatcroft, Commercial Director at Source BioScience. "We had already forged a strong relationship with OGT and worked together on several projects. With this acquisition, customers can now benefit from laboratory services from Source BioScience in conjunction with OGT's analysis software."



Incorporated in 1903, the company was formerly known as Medical Solutions plc and changed its name to Source BioScience plc in March 2008. It has grown both organically and through acquisitions in recent years. It now enjoys a strong position in the Healthcare, LifeSciences, Stability and Biostorage spaces, with a wide array of services and products available to customers around the world. One such service is their top-tier, next-generation sequencing service, which

employs prominent platforms such as the Illumina MiSeq, HiSeq and NextSeq technologies. Their Illumina CSPro accredited process and their highly-audited quality management system, has led Source BioScience to be one of Europe's leading providers of commercial sequencing for research and medical purposes.

Source Bioscience was attracted to OGT's genomics products portfolio for several reasons, says Mr. Wheatcroft. "After OGT changed their business

approach to focus more on their product offering, we agreed to acquire their next-generation sequencing services as well as their customer base. They have been growing at a compound annual growth rate of over 60% over the last four years, and they have further product growth opportunities from their recently launched SureSeq range of cancer panels and CytoSure Affirm non-invasive pre-natal test (NIPT) currently in clinical trials." Interesting in that regard is that Source BioScience has also gained access to OGT's analysis software as part of the deal.

In addition to integrating OGT's genomics portfolio, Source BioScience also plans to release a redesigned website with enhanced e-shop capabilities. As Mr. Wheatcroft puts it, the e-shop represents an opportunity to move into the new era, in which decision-makers purchase equipment or products largely online, even in the highly sophisticated field of genomics. "Our new website will allow companies and researchers to purchase a clone or clone library, complimentary antibodies, reagents and kits for use in advanced research in an easy, accessible and quick process."



Source BioScience
1 Orchard Place
Nottingham Business Park
Nottingham NG8 6PX
United Kingdom
Website: www.sourcebioscience.com